Clinical trial results found the tremor reduction is maintained one year after
treatment…patients are just very impressed with the results.
Clinical trial results found the tremor reduction is maintained one year after
treatment…patients are just very impressed with the results.
1) FDA labeling: The Exablate Neuro is intended for use in the unilateral thalamotomy treatment of idiopathic essential tremor patients with medication-refractory tremor. Patients must be at least age 22.
Disclaimer: The information provided here should not be considered medical advice. Please consult with a qualified physician for diagnosis and treatment. Patient testimonials may not be representative of all treatment outcomes.
Risks associated with any thalamotomy include transient and/or permanent sensory paresthesias, numbness, imbalance, and/or gait disturbance. These events are generally transient and mild or moderate in severity. Risks and adverse events also associated with the Exablate Neuro treatment include brief sonication-related pain, brief sonication-related dizziness and nausea or potential for deep vein thrombosis associated with lengthy time on the treatment bed.